Recently (May 2018) a study in Botswana reported an increased incidence (0.9%) of neural tube defects (NTDs) amongst infants born to women who received dolutegravir (DTG) at conception or early in the first trimester, compared to 0.1% NTDs observed with other antiretrovirals.Based on these findings the EMA, FDA and WHO issued a safety alert on the use of dolutegravir during conception, and advise not to prescribe dolutegravir for women of child bearing potential who are trying to become pregnant. This underlines the importance of prospective studies in pregnancy.
In Clinical Pharmacokinetics David Burger, Angela Colbers, Rob ter Heine en Ruben van der Galiën discuss that although yearly over a million of women with HIV get pregnant, it is often still unknown whether treatment with HIV-integrase inhibitors results in adequate drug exposure. The major mechanisms between altered exposure, the clinical implication and the remaining knowledge gaps are discussed.
Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps.
van der Galiën R, Ter Heine R, Greupink R, Schalkwijk SJ, van Herwaarden AE, Colbers A, Burger DM.
David Burger, Angela Colbers and Rob ter Heine are members of theme Infectious diseases and global health.
Related news items
The European Hector Research Award in HIV 2021 awarded to Angela Colbers and David Burger2 November 2021
On Friday 29 October 2021, during the 18th European AIDS Conference in London, the Hector Research Award for the best scientific article related to clinical or epidemiological HIV research was presented to Angela Colbers and David Burger, both working in the Pharmacy of the RadboudUMC.read more
Rob Aarnoutse is appointed as professor in Translation pharmacology of antimicrobial agents in particular drugs for tuberculosis25 January 2021
Hospital pharmacist and clinical pharmacologist Rob Aarnoutse is appointed as professor in ‘Translation pharmacology of antimicrobial agents, in particular drugs for tuberculosis’ at Radboud University / Radboudumc, starting 16 November 2020.read more
Radboudumc research leads to simplified dose of HIV medication for children31 August 2020
For children living with HIV, an adapted, simpler combination therapy is now available. Thanks to research by the Radboudumc, it is now clear that the use of one easily available tablet of dolutegravir in children gives just as good treatment results as a combination of several.read more
Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2)12 May 2020
In Lancet HIV RIHS researchers Angela Colbers and David Burger showed in an open-label, randomized controlled trial, that, when initiated in the 3rd trimester of pregnancy, achievement of VL <50cp/mL at delivery was more likely with dolutegravir-based therapy than with efavirenz-based regimens.read more
The effect of pregnancy on the pharmacokinetics of dolutegravir in women living with HIV17 March 2020
In Clinical infectious diseases RIHS researchers Pauline Bollen, Jolien Freriksen, Angela Colbers and David Burger together with researchers of the PANNA network showed that dolutegravir use in pregnancy results in effective plasma concentrations.read more